- Home
- VIGL vs DRTS Comparison
VIGL vs DRTS Comparison
Compare VIGL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- DRTS
- Stock Information
- Founded
- VIGL 2020
- DRTS 2015
- Country
- VIGL United States
- DRTS Israel
- Employees
- VIGL N/A
- DRTS N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- VIGL Health Care
- DRTS Health Care
- Exchange
- VIGL Nasdaq
- DRTS Nasdaq
- Market Cap
- VIGL 141.1M
- DRTS 159.4M
- IPO Year
- VIGL 2022
- DRTS N/A
- Fundamental
- Price
- VIGL $3.42
- DRTS $2.28
- Analyst Decision
- VIGL Buy
- DRTS Strong Buy
- Analyst Count
- VIGL 5
- DRTS 3
- Target Price
- VIGL $16.60
- DRTS $8.00
- AVG Volume (30 Days)
- VIGL 121.7K
- DRTS 17.5K
- Earning Date
- VIGL 08-13-2024
- DRTS 08-14-2024
- Dividend Yield
- VIGL N/A
- DRTS N/A
- EPS Growth
- VIGL N/A
- DRTS N/A
- EPS
- VIGL N/A
- DRTS N/A
- Revenue
- VIGL N/A
- DRTS N/A
- Revenue This Year
- VIGL N/A
- DRTS N/A
- Revenue Next Year
- VIGL N/A
- DRTS N/A
- P/E Ratio
- VIGL N/A
- DRTS N/A
- Revenue Growth
- VIGL N/A
- DRTS N/A
- 52 Week Low
- VIGL $2.47
- DRTS $1.75
- 52 Week High
- VIGL $9.24
- DRTS $3.90
- Technical
- Relative Strength Index (RSI)
- VIGL 46.18
- DRTS 53.84
- Support Level
- VIGL $3.20
- DRTS $2.23
- Resistance Level
- VIGL $3.78
- DRTS $2.46
- Average True Range (ATR)
- VIGL 0.30
- DRTS 0.11
- MACD
- VIGL 0.03
- DRTS 0.01
- Stochastic Oscillator
- VIGL 36.67
- DRTS 45.59
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.